Moreover, a recent phase I clinical trial demonstrated that pegylated IL-10 in combination with anti-(α)PD-1 therapy elicited robust anti-tumour immune responses and an improvement in clinical outcomes in patients with renal and non-small-cell carcinoma [20]. Here, PDCD1 is linked to neoplasm.